Related Experiment Video
Updated: Feb 28, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
TREX1 Cuts Down on Cancer Immunogenicity
Takahiro Yamazaki1, Lorenzo Galluzzi2
1Department of Radiation Oncology, Weill Cornell Medical College, 10065 New York, NY, USA.
Abstract:
Demaria and colleagues have recently identified three prime repair exonuclease 1 (TREX1) as a key determinant for the limited immunogenicity of cancer cells responding to single high-dose radiation. TREX1 stands out as a promising target for the development of novel strategies to boost anticancer immune responses driven by radiation therapy (RT).
Insights
Researchers found that the enzyme prime repair exonuclease 1 (TREX1) limits immune responses to radiation therapy. Targeting TREX1 may enhance cancer cell immunogenicity and improve radiation therapy effectiveness.
Area of Science:
- Oncology
- Immunology
- Radiation Biology
Background:
- Radiation therapy (RT) is a cornerstone of cancer treatment.
- The immunogenicity of cancer cells influences RT efficacy.
- Limited tumor immunogenicity can hinder treatment outcomes.
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Targeted Cancer Therapies
There are several types of targeted therapies against...

